Early safety and efficacy data from a phase i/ii trial of dzd4205, a selective jak1 inhibitor, in relapsed/refractory peripheral t‐cell lymphoma

W.‐S. Kim,D.‐H. Yoon,Y. Song,Y. Koh,J. Cao,D. Ji,H. Yang,H.‐S. Eom,H. Jing,J.‐Y. Kwak,W.‐S. Lee,J.‐S. Lee,H.‐J. Shin,J. Jin,M. Wang,J. Li,X. Huang,X. Deng,Z. Yang,J. Zhu

DOI: https://doi.org/10.1002/hon.57_2879

IF: 4.85

2021-01-01

Hematological Oncology

Abstract:Introduction: Relapsed or refractory (r/r) peripheral T cell lymphoma (PTCL) is an aggressive lymphoma with poor prognosis. Most approved therapies demonstrated overall response rates (ORR) < 30% and short progression free survival. DZD4205 (AZD4205), a potent and highly selective JAK1 inhibitor, demonstrated profound anti-tumor activity in T lymphoma cells in vitro and tumor xenograft in vivo, suggesting its potential as a therapeutic option for this unmet medical need. In this abstract, we reported the preliminary data from the ongoing phase I/II study of DZD4205 treating patients with r/r PTCL (NCT04105010, JACKPOT8). Methods: The JACKPOT8 study is an open label single arm study, which aims to assess the safety, tolerability and anti-tumor efficacy of DZD4205 in r/r PTCL. This study includes two parts. In Part A, subjects with r/r PTCL who relapsed from or were refractory/intolerant to systemic therapy were enrolled and dosed with DZD4205 at 150 mg or 250 mg once daily. In Part B, subjects received DZD4205 at a defined dose. Safety and efficacy were assessed according to CTCAE version 5.0 and 2014 Lugano classification, respectively. Results: As of December 7, 2020, a total of 47 subjects with r/r PTCL were dosed with DZD4205 (150 mg, n = 31; 250 mg, n = 16). Median age was 62.0 years (range: 29 - 79), and median prior systemic therapies were 2 lines (range: 1 - 8). Six subjects had undergone prior hematopoietic stem cell transplantation. Sixteen subjects had bone marrow involvement at the baseline. Histological subtypes included PTCL not otherwise specified (42.6%), angioimmunoblastic T cell lymphoma (42.6%), ALK negative anaplastic large cell lymphoma (6.4%), extra-nodal nasal NK/T cell lymphoma (6.4%) and monomorphic epitheliotropic intestinal T cell lymphoma (2.1%). Preliminary data showed that 41 subjects (87.2%) experienced treatment emergent adverse events (TEAEs), among whom 24 (51.1%) had ≥ grade 3 TEAEs. According to investigators, 16 subjects (34.0%) had ≥ grade 3 TEAEs possibly related to DZD4205. The most common (> 10%) ≥ grade 3 TEAEs included thrombocytopenia (23.4%), neutropenia (17.0%), and pneumonia (12.8%). Most TEAEs were manageable and reversible with or without dose modifications. As of December 7, 2020, 42 subjects (150 mg, n = 27; 250 mg, n = 15) completed at least one post-treatment tumor assessment. At 150 mg, 14 subjects showed tumor response, with ORR of 51.9%, among whom 6 (22.2%) had complete response. At 250 mg, 6 subjects showed tumor response, with ORR of 40.0%. Tumor response was observed in various subtypes. The median duration of response (DoR) was not reached, and the longest DoR was > 12 months. Patient enrolment is ongoing. The research was funded by: The research was funded by Dizal (Jiangsu) Pharmaceutical Co., Ltd. Ongoing Trial Keywords: Molecular Targeted Therapies, Aggressive T-cell non-Hodgkin lymphoma, Molecular Targeted Therapies No conflicts of interests pertinent to the abstract. SESSION 9: MANTLE CELL LYMPHOMA